WO2011060944A8 - Capsules de principes actifs pharmaceutiques et d'esters d'acides gras polyinsaturés - Google Patents

Capsules de principes actifs pharmaceutiques et d'esters d'acides gras polyinsaturés Download PDF

Info

Publication number
WO2011060944A8
WO2011060944A8 PCT/EP2010/007024 EP2010007024W WO2011060944A8 WO 2011060944 A8 WO2011060944 A8 WO 2011060944A8 EP 2010007024 W EP2010007024 W EP 2010007024W WO 2011060944 A8 WO2011060944 A8 WO 2011060944A8
Authority
WO
WIPO (PCT)
Prior art keywords
fatty acid
polyunsaturated fatty
active pharmaceutical
acid esters
pharmaceutical ingredient
Prior art date
Application number
PCT/EP2010/007024
Other languages
English (en)
Other versions
WO2011060944A2 (fr
WO2011060944A3 (fr
Inventor
Antonio PARENTE DUEÑA
Paolo Carminati
Original Assignee
Gp Pharm, S.A.
Defiante Farmaceutica, S.A.
Singrossi, Maria Gabriella
Carminati, Silvia
Carminati, Giuseppe Paolo
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gp Pharm, S.A., Defiante Farmaceutica, S.A., Singrossi, Maria Gabriella, Carminati, Silvia, Carminati, Giuseppe Paolo filed Critical Gp Pharm, S.A.
Publication of WO2011060944A2 publication Critical patent/WO2011060944A2/fr
Publication of WO2011060944A8 publication Critical patent/WO2011060944A8/fr
Publication of WO2011060944A3 publication Critical patent/WO2011060944A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A61K31/37—Coumarins, e.g. psoralen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4875—Compounds of unknown constitution, e.g. material from plants or animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5052—Proteins, e.g. albumin
    • A61K9/5057—Gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Dispersion Chemistry (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Botany (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne une composition pharmaceutique se présentant sous la forme d'une capsule qui contient des esters d'alkyle d'acides gras polyinsaturés (PUFA) et des principes actifs pour le traitement et/ou la prévention de maladies cardiovasculaires et/ou de processus inflammatoires.
PCT/EP2010/007024 2009-11-20 2010-11-19 Capsules de principes actifs pharmaceutiques et d'esters d'acides gras polyinsaturés WO2011060944A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ES200931026 2009-11-20
ES200931026A ES2363964B1 (es) 2009-11-20 2009-11-20 Cápsulas de principios activos farmacéuticos y ésteres de ácidos grasos poliinsaturados.

Publications (3)

Publication Number Publication Date
WO2011060944A2 WO2011060944A2 (fr) 2011-05-26
WO2011060944A8 true WO2011060944A8 (fr) 2011-10-27
WO2011060944A3 WO2011060944A3 (fr) 2012-05-03

Family

ID=43498493

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2010/007024 WO2011060944A2 (fr) 2009-11-20 2010-11-19 Capsules de principes actifs pharmaceutiques et d'esters d'acides gras polyinsaturés

Country Status (4)

Country Link
AR (1) AR079429A1 (fr)
ES (1) ES2363964B1 (fr)
TW (1) TW201141470A (fr)
WO (1) WO2011060944A2 (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2385240B1 (es) * 2010-07-26 2013-09-23 Gp-Pharm, S.A. Cápsulas de principios activos farmacéuticos y ácidos grasos poliinsaturados para el tratamiento de enfermedades de la próstata.
ITMI20112221A1 (it) 2011-12-05 2013-06-06 Altergon Sa Formulazioni stabili in capsule di gelatina molle di antiaggreganti piastrinici, acidi grassi omega-3 e amilosio
IN2014MN02245A (fr) * 2012-04-10 2015-10-09 Rubicon Res Private Ltd
WO2014007779A1 (fr) * 2012-07-06 2014-01-09 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Formulations de dexkétoprofène à désintégration orale
WO2014007780A1 (fr) * 2012-07-06 2014-01-09 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Formulations de dexkétoprofène à désintégration orale
CN103626689B (zh) * 2012-08-24 2016-03-09 上海医药工业研究院 一种阿哌沙班的中间体的制备方法
WO2015195990A1 (fr) * 2014-06-20 2015-12-23 Banner Life Sciences Llc Capsules de gélatine molle à libération immédiate remplies de liquide
CN106620707B (zh) * 2017-03-14 2019-06-07 牡丹江医学院 一种预防和治疗心肌缺血的药物组合物及其制备方法和用途
BR112020018277A2 (pt) 2018-03-15 2020-12-29 R.P. Scherer Technologies, Llc Cápsulas de gelatina mole entéricas
CN114869857B (zh) * 2022-05-12 2023-04-04 郑州大学第一附属医院 一种阿加曲班微粒、制剂及其制备方法

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5312473B1 (fr) 1971-05-24 1978-05-01
PH19942A (en) 1980-11-18 1986-08-14 Sintex Inc Microencapsulation of water soluble polypeptides
JPS5920230A (ja) 1982-07-19 1984-02-01 チバ−ガイギ−・アクチエンゲゼルシヤフト ピルプロフエン含有薬剤
JPS60100516A (ja) 1983-11-04 1985-06-04 Takeda Chem Ind Ltd 徐放型マイクロカプセルの製造法
US4609675A (en) 1984-08-17 1986-09-02 The Upjohn Company Stable, high dose, high bulk density ibuprofen granulations for tablet and capsule manufacturing
GB2209937B (en) 1987-09-21 1991-07-03 Depiopharm S A Water insoluble polypeptides
US4954346A (en) 1988-06-08 1990-09-04 Ciba-Geigy Corporation Orally administrable nifedipine solution in a solid light resistant dosage form
US4857552A (en) 1988-06-08 1989-08-15 E. I. Du Pont De Nemours And Co. Stable pharmaceutical composition
US5035896A (en) 1988-06-15 1991-07-30 Warner-Lambert Company Water insoluble drugs coated by coacervated fish gelatin
FR2660555B1 (fr) 1990-04-06 1994-09-16 Rhone Poulenc Sante Gelule huileuse de ketoprofene.
JPH05506011A (ja) 1990-04-11 1993-09-02 ジ・アップジョン・カンパニー 流動床コーティングによるイブプロフェンの味覚マスキング
CA2039742A1 (fr) 1990-04-23 1991-10-24 Andrew B. Dennis Comprimes pour ingredients pharmaceutiques sujets a problemes : composition et mode de preparation
CH683149A5 (fr) 1991-07-22 1994-01-31 Debio Rech Pharma Sa Procédé pour la préparation de microsphères en matériau polymère biodégradable.
ZA945944B (en) 1993-08-13 1996-02-08 Eurand America Inc Procedure for encapsulating nsaids
EP0672414B1 (fr) 1994-03-15 2005-06-08 Senju Pharmaceutical Co., Ltd. Méthode pour la stabilisation du pranoprofène et composition stable liquide contenant du pranoprofène
US5447729A (en) 1994-04-07 1995-09-05 Pharmavene, Inc. Multilamellar drug delivery systems
GB2290965A (en) 1994-07-11 1996-01-17 Therapicon Srl Multiple layer capsules for drugs
EP0839029A1 (fr) 1995-07-20 1998-05-06 PHARMACIA & UPJOHN COMPANY Solution claire et stable d'anti-inflammatoires non steroidiens a integrer dans des gelules de gelatine
WO1997033568A1 (fr) 1996-03-12 1997-09-18 Novartis Ag Gelules de gelatines remplies a degre de reticulation reduit
US6251426B1 (en) 1999-09-02 2001-06-26 Banner Pharmacaps, Inc. Ibuprofen-containing softgels
IL148685A0 (en) 1999-09-21 2002-09-12 Rtp Pharma Inc Surface modified particulate compositions of biologically active substances
US20030180352A1 (en) * 1999-11-23 2003-09-25 Patel Mahesh V. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
DE10026699A1 (de) 2000-05-30 2001-12-06 Basf Ag Formulierung auf Heparin-, Glycosaminoglycan- oder Heparinoidbasis und Verwendung der Formulierung sowie der Formulierungsgrundlage
WO2002015900A1 (fr) 2000-08-25 2002-02-28 Kowa Company, Ltd. Solutions d'ibuprofene destinees a etre mises en gelules et preparations en gelules
US6387400B1 (en) 2000-08-29 2002-05-14 R.P. Scherer Technologies, Inc. Process for preparing pharmaceutical compositions for use with soft gelatin formulations
TWI277414B (en) 2001-01-12 2007-04-01 Baxter Int Esmolol formulation
US6673944B2 (en) 2001-02-28 2004-01-06 Taro Pharmaceutical Industries, Ltd. Preparation of warfarin sodium from warfarin acid
ITMI20020731A1 (it) * 2002-04-08 2003-10-08 Ibsa Inst Biochimique Sa Composizioni farmaceutiche per acido acetilsalicilico e oli omega-3
ITFI20020144A1 (it) 2002-08-01 2004-02-02 Menarini Farma Ind Formulazioni topiche stabilizzate contenenti ketoprofene.
US20040115226A1 (en) 2002-12-12 2004-06-17 Wenji Li Free-flowing solid formulations with improved bio-availability of poorly water soluble drugs and process for making the same
GB0325603D0 (en) 2003-11-03 2003-12-10 Sandoz Ag Organic compounds
JP2007512372A (ja) 2003-11-25 2007-05-17 エスビー・ファルムコ・プエルト・リコ・インコーポレイテッド カルベジロール塩、対応する組成物、送達および／または治療方法
US20080311207A1 (en) 2004-09-08 2008-12-18 Manoj Varshney Micelles and Nanoemulsions for Preventive and Reactive Treatment of Atherosclerosis
JP4509118B2 (ja) 2004-10-06 2010-07-21 エルメッド エーザイ株式会社 医薬組成物及びその製造方法、並びに医薬組成物におけるジヒドロピリジン系化合物の安定化方法
ES2255426B1 (es) * 2004-10-19 2007-08-16 Gp Pharm, S.A. Formulacion farmaceutica que comprende microcapsulas de estatinas suspendidas en ester alquilicos de acidos grasos poliinsaturados (pufa).
EP1846040A2 (fr) 2005-01-28 2007-10-24 Collegium Pharmaceutical, Inc. Excipients non aqueux non ioniques pour administration topique et par voie orale d'agents actifs lies a un support
PT1688129E (pt) 2005-02-02 2015-11-04 Omega Pharma Innovation & Dev Nv Nova formulação terapêutica
EP2374508A1 (fr) * 2005-03-21 2011-10-12 Vicus Therapeutics SPE 1, LLC Combinaison des bloqeurs des recepteurs d'angiotensine et des AINS pour l'utilisation pour améliorer la cachexie/SIRS
EP1919285A2 (fr) 2005-07-28 2008-05-14 Reliant Pharmaceuticals, Inc. Traitement avec des inhibiteurs des canaux calciques a base de dihydropyridine et des acides gras omega-3 et produit combine contenant ceux-ci
WO2007103557A2 (fr) * 2006-03-09 2007-09-13 Reliant Pharmaceuticals, Inc. Revêtement de capsules avec des ingrédients pharmaceutiques actifs
KR100913791B1 (ko) 2006-07-21 2009-08-26 한미약품 주식회사 (ｓ)-(-)-암로디핀 캠실레이트 또는 이의 수화물 및 이를함유하는 약학적 조성물
WO2008062435A2 (fr) 2006-08-15 2008-05-29 Alkem Laboratories Ltd. Formes galéniques stabilisées de bésylate d'amlodipine
EP1894561A1 (fr) 2006-08-30 2008-03-05 Dr. Reddy's Laboratories Ltd. Compositions pharmaceutiques de dipyridamole
EP1903046B1 (fr) 2006-09-25 2011-02-16 Adamed SP. Z O.O. Nouveau sel de clopidogrel et ses formes cristallines
AU2007322291A1 (en) 2006-10-13 2008-05-29 Reliant Pharmaceuticals, Inc. Treatment with antiarrhythmics and omega-3 fatty acids and a combination product thereof
US7749537B2 (en) 2006-12-04 2010-07-06 Scolr Pharma, Inc. Method of forming a tablet
WO2008070950A1 (fr) 2006-12-13 2008-06-19 Laboratoires Mauves Inc. Formulations de solutions pharmaceutiques pour une encapsulation dans des capsules de gélatine ou autres formes posologiques
KR20080055356A (ko) 2006-12-15 2008-06-19 에스케이케미칼주식회사 보관안정성이 우수한 클로피도그렐 함유 포접 복합체
WO2008088808A1 (fr) 2007-01-16 2008-07-24 Reliant Pharmaceuticals, Inc. Traitement par médicaments anti-inflammatoires non stéroïdiens et acides gras oméga-3, et produit de combinaison de ceux-ci
BRPI0810168A2 (pt) 2007-04-09 2014-12-30 Usv Ltd Composições farmacêuticas de bissulfato de clopidogrel e processos de preparação das mesmas
CA2685593A1 (fr) * 2007-05-01 2008-11-06 Sigmoid Pharma Limited Compositions pharmaceutiques combinees

Also Published As

Publication number Publication date
ES2363964A1 (es) 2011-08-22
TW201141470A (en) 2011-12-01
WO2011060944A2 (fr) 2011-05-26
WO2011060944A3 (fr) 2012-05-03
ES2363964B1 (es) 2012-08-22
AR079429A1 (es) 2012-01-25

Similar Documents

Publication Publication Date Title
WO2011060945A3 (fr) Capsules de principes actifs pharmaceutiques et d'esters d'acides gras polyinsaturés pour le traitement de maladies cardiovasculaires
WO2011060944A3 (fr) Capsules de principes actifs pharmaceutiques et d'esters d'acides gras polyinsaturés
WO2012013331A3 (fr) Capsules d'ingrédients pharmaceutiques actifs et d'acides gras polyinsaturés pour le traitement de maladies de la prostate
PH12016500216B1 (en) Stable pharmaceutical composition and methods of using same
WO2009091538A8 (fr) Composition pharmaceutique et méthode permettant de traiter l'hypertriglycéridemie et l'hypercholestérolémie chez des mammifères
NZ734905A (en) Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same
WO2014005013A3 (fr) Procédés de réduction du risque d'un événement cardiovasculaire chez un sujet soumis à un traitement par une statine
NZ618734A (en) Polyunsaturated fatty acids for the treatment of diseases related to cardiovascular, metabolic and inflammatory disease areas
IL210233A (en) Formulation of omega-3 fatty acid containing epa and dha and no other active ingredients other than omega-3 fatty acids
SG10201405994UA (en) Pharmaceutical Composition Comprising Omega-3 Fatty Acid And Hydroxy-derivative Of A Statin And Methods Of Using Same
NZ595204A (en) Compositions comprising a fatty acid oil mixture and a surfactant, and methods and uses thereof
NZ600721A (en) Capsule formulation
MY165048A (en) Dpa-enriched compositions of omega-3 polyunsaturated fatty acids in free acid form
GB2459809A (en) Fatty acid formulations and methods of use thereof
MX2016004487A (es) Capsulas blandas de capa entérica que constan de ácidos grasos poli insaturados.
WO2010129565A3 (fr) Compositions, procédés et trousses pour des acides gras polyinsaturés provenant de microalgues
EP2506848A4 (fr) Substances permettant d'atténuer la survenue d'événements cardiaques majeurs qui contiennent un extrait de levure de riz rouge et des acides gras insaturés oméga 3 ou leur dérivé
WO2011051354A3 (fr) Compositions pharmaceutiques transdermiques contenant des agents actifs
HUE050830T2 (hu) Sztatinok és omega-3 zsírsavak gyógyászati kiszerelése kapszulázáshoz
WO2011097276A8 (fr) Procédés et compositions pour traiter l'arthrite par de l'acide docosahexaénoïque
GEP20125464B (en) Dha esters and use thereof in treatment and prevention of cardiovascular disease
WO2007090408A3 (fr) Comprimés enrobés, leurs procédés de préparation, et utilisations associées
WO2010136900A3 (fr) Procédés d'utilisation de l'huile de krill à des fins de traitement des facteurs de risque associés aux affections métaboliques, cardiovasculaires et inflammatoires
WO2013136183A3 (fr) Forme d'administration d'une composition à base d'acides gras oxydables
MX2009004339A (es) Alcoholes de acido graso.

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10788004

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 10788004

Country of ref document: EP

Kind code of ref document: A2